The BiTE product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful ‘ killer cells’ of the human immune system is based. Adecatumumab , a recombinant human monoclonal antibody that is directed EpCAM expressing tumors, two Phase 2a clinical trials been completed been completed in patients with breast cancer, and other patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. Micromet has established partnerships with MedImmune and Merck Serono.. About Micromet, Two product candidates are currently in clinical trials. MT103 , the first product candidate to Micromet’s novel BiTE product development platform, Forward-Looking Statements a Phase 1 clinical trial for the treatment of patients with non-Hodgkin’s lymphoma.
This is another example of our society approach to the use of our optimization technologies and know-how to produce antibodies with improved pharmacological activity for achieving clinical benefit,’said Nicholas Niccolaides, President and Chief Executive Officer of Morphotek. ‘This molecule join our portfolio of therapeutic antibodies as we pursue our strategy of becoming a global leader in the development of innovative immunotherapies for the treatment of cancer, inflammation and infectious diseases. ‘ – ‘We are pleased to see this program forward in development with our partner Morphotek,’said Christian Itin, President and Chief Executive Officer of Micromet.Mode of action – As the first a new class of cardiac treatment Inodilators have Vetmedin a dual mechanism, that increase directly to the heart as a calcium sensitizer to contractile and both the the peripheral circulation by selective phosphodiesterase III inhibition manufacture peripheral and coronary vasodilatation. As a result, Vetmedin increases cardiac output and only cut down the preload and afterload. Furthermore Vetmedin heart minute volume effectiveness efficiency inside the myofilaments, with no increase in myocardial energy demand.